Historical Valuation
Oramed Pharmaceuticals Inc (ORMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.43 is considered Undervalued compared with the five-year average of -10.64. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 93.47 to 994.97 according to relative valuation methord. Compared to the current price of 3.48 USD , Oramed Pharmaceuticals Inc is Undervalued By 96.28%.
Relative Value
Fair Zone
93.47-994.97
Current Price：3.48
96.28%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Oramed Pharmaceuticals Inc (ORMP) has a current Price-to-Book (P/B) ratio of 0.58. Compared to its 3-year average P/B ratio of 0.64 , the current P/B ratio is approximately -8.20% higher. Relative to its 5-year average P/B ratio of 1.83, the current P/B ratio is about -68.01% higher. Oramed Pharmaceuticals Inc (ORMP) has a Forward Free Cash Flow (FCF) yield of approximately -9.16%. Compared to its 3-year average FCF yield of -13.31%, the current FCF yield is approximately -31.20% lower. Relative to its 5-year average FCF yield of -11.81% , the current FCF yield is about -22.45% lower.
P/B
Median3y
0.64
Median5y
1.83
FCF Yield
Median3y
-13.31
Median5y
-11.81
Competitors Valuation Multiple
AI Analysis for ORMP
The average P/S ratio for ORMP competitors is 10.01, providing a benchmark for relative valuation. Oramed Pharmaceuticals Inc Corp (ORMP.O) exhibits a P/S ratio of 0.43, which is -95.68% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ORMP
1Y
3Y
5Y
Market capitalization of ORMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ORMP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ORMP currently overvalued or undervalued?
Oramed Pharmaceuticals Inc (ORMP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.43 is considered Undervalued compared with the five-year average of -10.64. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 93.47 to 994.97 according to relative valuation methord. Compared to the current price of 3.48 USD , Oramed Pharmaceuticals Inc is Undervalued By 96.28% .
What is Oramed Pharmaceuticals Inc (ORMP) fair value?
ORMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 93.47 to 994.97 according to relative valuation methord.
How does ORMP's valuation metrics compare to the industry average?
The average P/S ratio for ORMP's competitors is 10.01, providing a benchmark for relative valuation. Oramed Pharmaceuticals Inc Corp (ORMP) exhibits a P/S ratio of 0.43, which is -95.68% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Oramed Pharmaceuticals Inc (ORMP) as of Jan 09 2026?
As of Jan 09 2026, Oramed Pharmaceuticals Inc (ORMP) has a P/B ratio of 0.58. This indicates that the market values ORMP at 0.58 times its book value.
What is the current FCF Yield for Oramed Pharmaceuticals Inc (ORMP) as of Jan 09 2026?
As of Jan 09 2026, Oramed Pharmaceuticals Inc (ORMP) has a FCF Yield of -9.16%. This means that for every dollar of Oramed Pharmaceuticals Inc’s market capitalization, the company generates -9.16 cents in free cash flow.
What is the current Forward P/E ratio for Oramed Pharmaceuticals Inc (ORMP) as of Jan 09 2026?
As of Jan 09 2026, Oramed Pharmaceuticals Inc (ORMP) has a Forward P/E ratio of 1.05. This means the market is willing to pay $1.05 for every dollar of Oramed Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Oramed Pharmaceuticals Inc (ORMP) as of Jan 09 2026?
As of Jan 09 2026, Oramed Pharmaceuticals Inc (ORMP) has a Forward P/S ratio of 0.43. This means the market is valuing ORMP at $0.43 for every dollar of expected revenue over the next 12 months.